| Multicenter, Open-label, Safety and Tolerability Study (NCT01649557) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-08-01 |
| Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine (NCT01047215) | Taichung Veterans General Hospital | 2009-08-01 |
| Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia (NCT01010477) | Rutgers, The State University of New Jersey | 2009-08-01 |
| Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants (NCT01387542) | Janssen-Cilag Ltd.,Thailand | 2009-08-01 |
| The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients (NCT01137799) | Janssen Pharmaceutica N.V., Belgium | 2009-08-01 |
| Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs (NCT01479413) | Chang Gung Memorial Hospital | 2009-08-01 |
| Metabolic Syndrome in Patients With First-episode Schizophrenia (NCT00957294) | Aarhus University Hospital | 2009-08-01 |
| Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia (NCT00864825) | Sheba Medical Center | 2009-08-01 |
| A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended (NCT00922090) | AstraZeneca | 2009-07-01 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (NCT00905307) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-07-01 |
| Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia (NCT00833976) | Massachusetts General Hospital | 2009-07-01 |
| Extended Specialized Assertive Intervention for First Episode Psychosis (NCT00914238) | University of Copenhagen | 2009-07-01 |
| Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan (NCT01077687) | National Taiwan University Hospital | 2009-07-01 |
| Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) (NCT00934466) | Merck Sharp & Dohme LLC | 2009-07-01 |
| Once Weekly D-cycloserine for Schizophrenia (NCT00964041) | Massachusetts General Hospital | 2009-07-01 |
| Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network (NCT00930150) | National Institute of Mental Health (NIMH) | 2009-07-01 |
| Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning (NCT00937261) | University of California, Irvine | 2009-07-01 |
| A Repeat Dose Positron Emission Tomography Study With GSK1144814 (NCT01209039) | GlaxoSmithKline | 2009-07-01 |
| Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER (NCT02075528) | Taipei City Hospital | 2009-07-01 |
| Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia (NCT01034085) | National Institute on Drug Abuse (NIDA) | 2009-06-02 |
| Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls (NCT01214005) | Brown University | 2009-06-01 |
| Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients (NCT00919607) | AstraZeneca | 2009-06-01 |
| Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients (NCT00921804) | AstraZeneca | 2009-06-01 |
| Serum Clozapine and Cognition (NCT00951418) | University of Aarhus | 2009-06-01 |
| InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics (NCT01026285) | Janssen-Cilag International NV | 2009-06-01 |
| Polypharmacy in Clozapine-resistant Schizophrenia (NCT00918021) | Niuvanniemi Hospital | 2009-06-01 |
| Oculomotor and Spatial Cognition Deficits in Schizophrenia (NCT00931996) | University of Illinois at Chicago | 2009-06-01 |
| Role of Anti-Inflammatory Agents in Patients With Schizophrenia (NCT00929955) | Pakistan Institute of Living and Learning | 2009-06-01 |
| Open-label Study of Curcumin C-3 Complex in Schizophrenia (NCT01875822) | Woodbury, Michel, M.D. | 2009-06-01 |
| Biomarkers in Schizophrenia (NCT00817336) | Nathan Kline Institute for Psychiatric Research | 2009-06-01 |
| Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders (NCT00914030) | University Hospital, Strasbourg, France | 2009-06-01 |
| Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia (NCT00894842) | National Research Foundation, Singapore | 2009-06-01 |
| Vitamin D Supplementation in Psychiatric Illnesses (NCT01004354) | University of Massachusetts, Worcester | 2009-06-01 |
| Arithmetic Training With the Kumon Method for Cognition in Schizophrenia (NCT03055520) | University of Sao Paulo | 2009-06-01 |
| 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years (NCT00946985) | Ortho-McNeil Janssen Scientific Affairs, LLC | 2009-06-01 |
| A Study of Cariprazine in Patients With Chronic Stable Schizophrenia (NCT00839852) | Forest Laboratories | 2009-05-31 |
| A Shared Decision Making Training for Inpatients With Schizophrenia (NCT00885716) | Technical University of Munich | 2009-05-01 |
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients (NCT01043250) | Samsung Medical Center | 2009-05-01 |
| A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia (NCT00915512) | Janssen-Cilag Turkey | 2009-05-01 |
| Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder (NCT00892021) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-05-01 |
| Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome (NCT01714011) | University of Malaya | 2009-05-01 |
| Add On Treatment for Cognitive Deficits in Schizophrenia (NCT01346163) | University of Pennsylvania | 2009-04-01 |
| A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia (NCT01942382) | Janssen Pharmaceutical K.K. | 2009-04-01 |
| Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia (NCT00876304) | Taisho Pharmaceutical Co., Ltd. | 2009-04-01 |
| Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA) (NCT00885690) | University of Aarhus | 2009-04-01 |
| Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients (NCT00882518) | AstraZeneca | 2009-04-01 |
| Cognitive-Behavioral Therapy in Veterans With Schizophrenia (NCT00688259) | VA Office of Research and Development | 2009-04-01 |
| Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome (NCT00857818) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-04-01 |
| An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder (NCT00861003) | Korea University Guro Hospital | 2009-04-01 |
| Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia (NCT00425815) | University of California, Los Angeles | 2009-04-01 |
| Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia (NCT00873249) | AstraZeneca | 2009-04-01 |
| Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia (NCT00847600) | Sha'ar Menashe Mental Health Center | 2009-03-01 |
| Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia (NCT00981526) | University of Massachusetts, Worcester | 2009-03-01 |
| Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia (NCT01047592) | Chang-Hua Hospital | 2009-03-01 |
| Subjective Well Being of Schizophrenic Patients in Greece (NCT00857064) | AstraZeneca | 2009-03-01 |
| A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients (NCT00845026) | Denovo Biopharma LLC | 2009-03-01 |
| A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations (NCT01075373) | National Taiwan University Hospital | 2009-03-01 |
| Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments (NCT00894296) | Shalvata Mental Health Center | 2009-03-01 |
| A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) (NCT00827918) | Merck Sharp & Dohme LLC | 2009-03-01 |
| A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia (NCT00743847) | Pfizer | 2009-03-01 |
| Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine (NCT00934908) | Medical University of South Carolina | 2009-03-01 |
| Effects of Delta-9-THC and Iomazenil in Healthy Humans (NCT00982982) | Yale University | 2009-02-11 |
| Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia (NCT00870909) | Hôpital le Vinatier | 2009-02-02 |
| Seroquel XR in Adults With Schizophrenia (NCT00852631) | AstraZeneca | 2009-02-01 |
| NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia (NCT00833456) | AstraZeneca | 2009-02-01 |
| Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia (NCT00588731) | Yale University | 2009-02-01 |
| A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder (NCT01094249) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-02-01 |
| D-serine Monotherapy for Schizophrenia (NCT00816894) | Herzog Hospital | 2009-01-01 |
| Shiatsu Adjuvant Therapy And Placebo For Schizophrenia (NCT00788970) | Herzog Hospital | 2009-01-01 |
| Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment (NCT00789022) | Shalvata Mental Health Center | 2009-01-01 |
| Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia (NCT00825539) | Novartis Pharmaceuticals | 2009-01-01 |
| Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia (NCT01279213) | Universidad Nacional de Rosario | 2009-01-01 |
| Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years (NCT01362439) | Janssen-Cilag S.p.A. | 2009-01-01 |
| Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia (NCT01055509) | University of Southern Denmark | 2009-01-01 |
| The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study) (NCT00816907) | National Institute of Mental Health (NIMH) | 2009-01-01 |
| Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing (NCT01602263) | Johns Hopkins University | 2009-01-01 |
| Study of Mental Care in Spain (NCT00824031) | AstraZeneca | 2009-01-01 |
| Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients (NCT00781794) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-01-01 |
| 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study (NCT00818298) | Centre for Addiction and Mental Health | 2009-01-01 |
| A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men (NCT01060228) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-01-01 |
| Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia (NCT00825045) | Centre for Addiction and Mental Health | 2008-12-01 |
| Specific Cognitive Remediation for Schizophrenia (NCT01607424) | Hôpital le Vinatier | 2008-12-01 |
| Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712 (NCT00805454) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-12-01 |
| Clinical Benefits of Seroquel XR in Anxiety Disorder (NCT01672554) | Corporation de Recherche en Neuropsycho Pharmacologie de Quebec | 2008-12-01 |
| A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone (NCT01979679) | University of California, Irvine | 2008-12-01 |
| Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS) (NCT01154829) | University of Copenhagen | 2008-12-01 |
| Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (NCT00731549) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-12-01 |
| Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia (NCT00793780) | Yale University | 2008-12-01 |
| Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia (NCT00821600) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-12-01 |
| rTMS Effects on Smoking Cessation and Cognition in Schizophrenia (NCT00736710) | Centre for Addiction and Mental Health | 2008-12-01 |
| Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects (NCT01268124) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-12-01 |
| Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment (NCT00809731) | AstraZeneca | 2008-12-01 |
| A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia (NCT00817648) | Shanghai Mental Health Center | 2008-12-01 |
| Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia (NCT00802100) | National Institute of Mental Health (NIMH) | 2008-12-01 |
| Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (NCT00798109) | Assistance Publique - Hôpitaux de Paris | 2008-11-01 |
| Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia (NCT00810667) | H. Lundbeck A/S | 2008-11-01 |
| The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics (NCT02142556) | Tri-Service General Hospital (TSGH) | 2008-11-01 |
| Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy (NCT00791440) | New York State Psychiatric Institute | 2008-11-01 |
| Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) (NCT00779506) | AstraZeneca | 2008-11-01 |
| Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia (NCT00827840) | Chonnam National University Hospital | 2008-11-01 |